AstraZeneca (AZN.US) faces setback in Phase III clinical trial of breast cancer drug Etcamah, potentially impacting billions of dollars in sales
智通财经2026/09/14 08:41Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
According to Zhitong Finance APP, AstraZeneca (AZN.US) announced last Friday that its oral selective estrogen receptor degrader (SERD) Etcamah (camizestrant) combined with Palbociclib for first-line treatment of ER-positive, HER2-negative advanced breast cancer in the SERENA-4 phase III trial did not meet the primary endpoint. Although there was a numerical improvement in progression-free survival (PFS), it did not reach statistical significance.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Central Bank: RMB loans increased by 10.44 trillion yuan in the first eight months
智通财经•2026/09/14 09:21
Crypto prices
More
Bitcoin
BTC
$77,870.84
+1.53%
Ethereum
ETH
$2,521.32
+1.62%
Tether USDt
USDT
$0.9996
-0.01%
BNB
BNB
$723.19
+1.06%
XRP
XRP
$1.39
+3.57%
USDC
USDC
$0.9998
-0.00%
Solana
SOL
$101.53
+1.80%
TRON
TRX
$0.3402
+0.06%
Hyperliquid
HYPE
$79.31
+1.80%
Zcash
ZEC
$1,135.6
+5.10%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now